Jiang Y Z, Mavroudis D A, Dermime S, Molldrem J, Hensel N F, Barrett A J
Bone Marrow Transplantation Unit, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Bone Marrow Transplant. 1997 May;19(9):899-903. doi: 10.1038/sj.bmt.1700769.
New understanding of the alloresponse following bone marrow transplantation supports the possibility that the graft-versus-host disease (GVHD) response can be separated from a favorable graft-versus-leukemia (GVL) effect. We used chronic myeloid leukemia (CML) cells to generate 122 recipient-reactive T cell clones from a closely HLA-matched sibling responder. Clones were tested for their proliferative response to stimulator CML cells or PHA-transformed (non-leukemic) lymphoblasts. Of 78 clones tested, 32 recognized both leukemia cells and PHA blasts, 19 only CML and four only PHA blasts. The remainder were non-specific responders. This functional specificity corresponded to distinct patterns of T cell receptor (TCR) V beta usage: clones recognizing CML cells preferentially used V beta 5, V beta 6/7 while clones recognizing both CML and PHA blasts or only PHA blasts preferentially used V beta 3 and V beta 8. It may therefore be possible to identify in vitro-generated myeloid leukemia-restricted donor T cells by their pattern of V beta usage. TCR V beta antibodies could thus be used to select and expand leukemia-restricted donor T cells for transfusion after BMT to specifically enhance the GVL response.
对骨髓移植后同种异体反应的新认识支持了移植物抗宿主病(GVHD)反应与有益的移植物抗白血病(GVL)效应可以分离的可能性。我们使用慢性粒细胞白血病(CML)细胞,从一名HLA紧密匹配的同胞反应者中产生了122个受体反应性T细胞克隆。检测这些克隆对刺激物CML细胞或PHA转化的(非白血病)淋巴母细胞的增殖反应。在测试的78个克隆中,32个既能识别白血病细胞又能识别PHA母细胞,19个仅能识别CML细胞,4个仅能识别PHA母细胞。其余的是非特异性反应者。这种功能特异性与T细胞受体(TCR)Vβ使用的不同模式相对应:优先识别CML细胞的克隆使用Vβ5、Vβ6/7,而既能识别CML细胞又能识别PHA母细胞或仅能识别PHA母细胞的克隆优先使用Vβ3和Vβ8。因此,有可能通过其Vβ使用模式在体外鉴定产生的髓系白血病限制性供体T细胞。因此,TCR Vβ抗体可用于选择和扩增白血病限制性供体T细胞,以便在骨髓移植后进行输血,以特异性增强GVL反应。